What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to evaluate the magnitude and frequency of within - day glycemic variability (GV) in hospitalized type 2 diabetic patients and explore the factors influencing within - day GV. Specifically, the study focuses on the following aspects: 1. **Magnitude of within - day GV**: The magnitude of within - day GV is evaluated by calculating the coefficient of variation (%CV). The target %CV range is defined as less than 24.4%. 2. **Frequency of within - day GV**: The frequency of within - day GV is evaluated by the time that consecutive days (CD) are maintained within the target %CV range. The main indicators include the consecutive days after first reaching the target (%CV range) and the maximum consecutive days (Max - CD). 3. **Factors influencing within - day GV**: Cox regression and Poisson regression models are used to analyze the factors influencing the magnitude and frequency of within - day GV, including patients' age, gender, disease duration, body mass index (BMI), low - density lipoprotein (LDL), glycated hemoglobin (HbA1c), C - peptide level, comorbidities, and the types of hypoglycemic drugs used. ### Main findings - **Magnitude of within - day GV**: 86.57% of patients reduced the magnitude of within - day GV before the 6th day of hospitalization. - **Frequency of within - day GV**: 66.57% of patients could only maintain less than two days after first reaching the target %CV range; 69.71% of patients had a maximum consecutive days (Max - CD) of less than four days. - **Influencing factors**: - **Reducing postprandial blood glucose fluctuations**: Reducing the amplitude of postprandial blood glucose fluctuations (HR: 0.81, 95% CI: 0.77 - 0.85; IRR: 0.72, 95% CI: 0.69 - 0.74) helps to reduce the magnitude and frequency of within - day GV. - **Using α - glucosidase inhibitors**: Using α - glucosidase inhibitors (IRR: 1.1, 95% CI: 1.01 - 1.18) helps to reduce the magnitude and frequency of within - day GV. - **Using glucagon - like peptide - 1 receptor agonists (GLP - 1 agonist)**: Using GLP - 1 receptor agonists (IRR: 1.30, 95% CI: 1.02 - 1.65) helps to reduce the magnitude and frequency of within - day GV. - **Using insulin**: Using insulin (HR: 0.64, 95% CI: 0.55 - 0.75; IRR: 0.86, 95% CI: 0.79 - 0.93) and meglitinides (HR: 0.47, 95% CI: 0.31 - 0.73; IRR: 0.84, 95% CI: 0.73 - 0.97) may increase the frequency of within - day GV. ### Conclusion Although the magnitude of within - day GV in hospitalized type 2 diabetic patients decreases during hospitalization, the frequency of within - day GV increases. Using drugs that can reduce postprandial blood glucose can reduce the risk of frequent within - day GV. These findings emphasize that in inpatient management, in addition to controlling chronic hyperglycemia, attention also needs to be paid to the stability of blood glucose fluctuations to reduce the risk of hypoglycemia and hyperglycemia.

Assessing the temporal within-day glycemic variability during hospitalization in patients with type 2 diabetes patients using continuous glucose monitoring: a retrospective observational study

Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study

Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies

Glycemic variability: adverse clinical outcomes and how to improve it?

Establishment Of Normal Reference Ranges For Glycemic Variability In Chinese Subjects Using Continuous Glucose Monitoring

Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients

Observational study on stability of within-day glycemic variability of type 2 diabetes inpatients treated with decoctions of traditional Chinese medicine

Impact of acute glycemic variability on short-term outcomes in patients with ST-segment elevation myocardial infarction: a multicenter population-based study

Investigating the Relationship between Morning Glycemic Variability and Patient Characteristics Using Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes

Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis

Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring

Association of long-term visit-to-visit glycemic variability with risk of adverse clinical outcomes in diabetic patients with heart failure with preserved ejection fraction

Relationship Between Early–phase Insulin Secretion and Blood Glucose Variability in Subject with Normal Glucose Regulation

A study of factors influencing long-term glycemic variability in patients with type 2 diabetes: a structural equation modeling approach

Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial

Visit‐to‐visit HbA1c variability and risk of potentially avoidable hospitalisations in adults with type 2 diabetes receiving outpatient care at a tertiary hospital

Impact of acute-phase insulin secretion on glycemic variability in insulin-treated patients with type 2 diabetes

Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus

Diabetic peripheral neuropathy and glycemic variability assessed by continuous glucose monitoring: A systematic review and meta-analysis

Personal and Social-Built Environmental Factors of Glucose Variability Among Multiethnic Groups of Adults With Type 2 Diabetes: Research Protocol Using Ecological Momentary Assessment, Continuous Glucose Monitoring, and Actigraphy